Myanmar vs Zimbabwe: Average cost of drugs for extensively drug-resistant tuberculosis
Myanmar
963 constant 2022 US$
in 2024
Zimbabwe
852 constant 2022 US$
in 2023
Myanmar rank
43rd
Zimbabwe rank
45th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Myanmar
- Zimbabwe
How they compare
Myanmar currently reports 963 constant 2022 US$ against 852 constant 2022 US$ in Zimbabwe, a difference of 111 constant 2022 US$.
That makes Myanmar's figure about 1.1 times Zimbabwe's.
The two have swapped places 3 times across 6 shared years of data; in 2017 it was Zimbabwe ahead.
Myanmar ranks 43rd and Zimbabwe ranks 45th of 56 countries.
Across the 2 decades both report, Myanmar averaged higher in 1 and Zimbabwe in 1.
Head to head by decade
| Decade | Myanmar | Zimbabwe | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 7,630 constant 2022 US$ | 8,999 constant 2022 US$ | 1,369 constant 2022 US$ | Zimbabwe |
| 2020s | 3,133 constant 2022 US$ | 917.33 constant 2022 US$ | 2,215 constant 2022 US$ | Myanmar |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Myanmar or Zimbabwe?
- Myanmar, at 963 constant 2022 US$ against 852 constant 2022 US$ in Zimbabwe as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Myanmar and Zimbabwe?
- 111 constant 2022 US$, with Myanmar ahead.
- How many years of comparable data are there for Myanmar and Zimbabwe?
- 6 years are reported by both, from 2017 to 2023.
- How do Myanmar and Zimbabwe rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Myanmar ranks 43rd and Zimbabwe ranks 45th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.